arrow
S

Sara Oresti

vita salute san-raffaele university
H指数:6
被引数:160

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Hyperprogression Upon Cemiplimab Alone or With Short Course Chemotherapy in PD-L1 ≥ 50% Non-small Cell Lung Cancer: A Biomarker Guided Multicenter International Phase 2 Trial-HYPERBOLIC Study

PD-L1 ≥ 50% 非小细胞肺癌中cemiplimab单药或联合短程化疗的超进展:一项生物标志物指导的多中心国际II期试验—HYPERBOLIC研究

2026-09-010
PRE
Outcomes of first-line chemo-immunotherapy in advanced non-squamous NSCLC according to KRAS status: An Italian real-world study

根据KRAS状态评估一线化疗联合免疫疗法在晚期非鳞状NSCLC中的疗效:一项意大利真实世界研究

2026-08-010
PRE
Family history enrichment in Non-Small cell Lung Cancer: A cross-sectional − prospective study to inform referral for germline testing

非小细胞肺癌中的家族史信息补充:一项用于指导胚系检测转诊的横断面-前瞻性研究

2026-02-260
OAAI
Impact of platinum-based chemotherapy and CTLA-4 inhibition on acquired resistance to first-line anti-PD-1/PD-L1 agents in non-small cell lung cancer: a systematic review and reconstructed individual patient data analysis

铂类化疗和CTLA-4抑制对非小细胞肺癌中一线抗PD-1/PD-L1药物获得性耐药的影响:一项系统综述和重构的个体患者数据分析

2025-09-020
PREAI
Assessing uncertainty and vulnerability of clinical trials with immune-checkpoint inhibitors and chemotherapy (ICI plus CT) in early stage non-small cell lung cancer (NSCLC) by informative censoring and survival inferred fragility index (SIFI)

评估免疫检查点抑制剂联合化疗(ICI plus CT)在早期非小细胞肺癌(NSCLC)临床试验中的不确定性和脆弱性,采用信息性删失和生存推断脆弱性指数(SIFI)进行分析。

2024-09-010
PRE
Clinical implications of the family history in patients with lung cancer: a systematic review of the literature and a new cross-sectional/prospective study design (FAHIC: lung)
2024-07-312
OAAI
Activity of osimeRTInib in non-small-cell lung Cancer with UNcommon epidermal growth factor receptor mutations: retrospective Observational multicenter study (ARTICUNO)

奥希替尼在具有罕见表皮生长因子受体突变的非小细胞肺癌中的活性: 回顾性观察性多中心研究 (ARTICUNO)

2024-06-011
OAAI
Sex dimorphism and cancer immunotherapy: May pregnancy solve the puzzle?
2023-12-013
PRE
Systematic review and meta-analysis of immune checkpoint inhibitors as single agent or in combination with chemotherapy in early-stage non-small cell lung cancer: Impact of clinicopathological factors and indirect comparison between treatment strategies
2023-12-0110
PRE
Evaluation of COVID-19 impact on DELAYing diagnostic-therapeutic pathways of lung cancer patients in Italy (COVID-DELAY study): fewer cases and higher stages from a real-world scenario
2022-04-0145
OAAI
Evaluation of COVID-19 impact on DELAYing diagnostictherapeutic pathways of lung cancer patients in Italy (COVID-DELAY study): fewer cases and higher stages from a real-world scenario (vol 7, 100406, 2022)
2022-04-012
OAAI